Providing ART to HIV seropositive persons who inject drugs: Implementing “Treatment as Prevention” in New York City
Methods: We recruited 3511 PWID from persons voluntarily entering drug detoxification and methadone maintenance treatment programs in New York City from 2001 to 2014. Informed consent was obtained, a structured interview was administered and HIV counseling and testing conducted. Questions included whether the participant had previously tested positive for HIV, and whether the participant had received ART medication in the previous 6 months. Department of Health surveillance data were utilized to estimate the percentage of PWID on ART who were at viral suppression.
Results: Heroin (injected) was the primary drug used. HIV prevalence declined significantly from14% in 2001 to 6% in 2012-2014. The percentage of self-reported HIV seropositive PWID receiving ART increased significantly, from 50% in 2001-2005 to 75% in 2012-2014. 75% of PWID on ART were at viral suppression in surveillance data, indicating that half or more of current HIV positive PWID in the city are at viral suppression.
Conclusions: Continued improvement in ART/TasP and maintenance of other prevention and care services should lead to an “End of the AIDS Epidemic” for PWID in the city.
Learning Areas:Biostatistics, economics
Public health or related research
Social and behavioral sciences
Evaluate progress in placing HIV seropositive persons who inject drugs (PWID) onto antiretroviral treatment (ART) in New York City over the last 15 years. Examine obstacles in linking to HIV care, receiving and ART and achieving viral suppression
Keyword(s): HIV/AIDS, Drug Abuse
Qualified on the content I am responsible for because: Dr. Des Jarlais is a leader in the fields of AIDS and injecting drug use, and has published extensively on these topics. He is active in international research, having collaborated on studies in many different countries. He serves as consultant to various institutions, including the CDC, NIDA, the National Academy of Sciences, and WHO.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.